129 Results for "

H ,K -ATPase

" in MedChemExpress (MCE) Product Catalog:
Products (129)

129 Results for "H ,K -ATPase" in MCE Product Catalog:

10
10 Publications Verification
Cat. No.: HY-B0113
CAS No.: 73590-58-6
Synonyms: H 16868
Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
loading...
    loading...
10
10 Publications Verification
Cat. No.: HY-B0113A
CAS No.: 95510-70-6
Synonyms: H 16868 sodium
Omeprazole (H 16868) sodium is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N2033
CAS No.: 18942-26-2
Chebulinic acid is a potent natural inhibitor of M. tuberculosis DNA gyrase, also can inhibit SMAD-3 phosphorylation, inhibit H+ K+-ATPase activity.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15295
CAS No.: 881681-01-2
Purity:  101.1%
Synonyms: TAK-438
Target:  

Proton Pump

Research Areas:  

Infection Inflammation/Immunology

Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-100007
CAS No.: 881681-00-1
Purity:  99.40%
Synonyms: TAK-438 free base
Target:  

Proton Pump Bacterial

Research Areas:  

Infection

Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B0656
CAS No.: 117976-89-3
Synonyms: LY307640
Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B0656A
CAS No.: 117976-90-6
Synonyms: LY307640 sodium
Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-100007A
CAS No.: 1957202-44-6
Synonyms: TAK-438 hydrochloride
Target:  

Proton Pump Bacterial

Research Areas:  

Infection Endocrinology Cancer

Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-17507
CAS No.: 102625-70-7
Synonyms: BY1023; SKF96022
Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-17507A
CAS No.: 138786-67-1
Synonyms: BY1023 sodium; SKF96022 sodium
Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-17507B
CAS No.: 164579-32-2
Synonyms: BY1023 sodium hydrate; SKF96022 sodium hydrate
Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-17021
CAS No.: 119141-88-7
Synonyms: (S)-Omeprazole; (-)-Omeprazole
Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-17623
CAS No.: 942195-55-3
Synonyms: CJ-12420; RQ-00000004
Tegoprazan (CJ-12420), a potassium-competitive acid blocker, is a reversible, orally active and highly selective inhibitor of gastric H +/K +-ATPase. Tegoprazan inhibits gastric acid secretion and motility against porcine, canine and human H +/K +-ATPase with IC50 values ranging from 0.29-0.52 μM in vitro. Tegoprazan significantly improves colitis and enhances the intestinal epithelial barrier function in mice. Tegoprazan is promising for research of Inflammatory bowel, gastric acid-related, motilityimpaired diseases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-17023
CAS No.: 161796-78-7
Synonyms: (S)-Omeprazole sodium; (-)-Omeprazole sodium
Research Areas:  

Endocrinology Cancer

Esomeprazole sodium ((S)-Omeprazole sodium) is a potent and orally active proton pump inhibitor. Esomeprazole reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases . Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-100414
CAS No.: 261944-46-1
Purity:  99.78%
Synonyms: BYK61359
Target:  

Proton Pump

Research Areas:  

Metabolic Disease

Soraprazan (BYK61359) is a selective, reversible K-competitive inhibitor of the H,K-ATPase (Ki=6.4 nM), with an IC50 of 0.19 μM in gastric glands. Soraprazan binds to the H,K-ATPase with a Kd of 28.27 nM. Soraprazan shows immediate inhibition of acid secretion and is more than 2000-fold selective for H,K-ATPase over Na,K- and Ca-ATPases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B1446
CAS No.: 161973-10-0
Synonyms: (S)-Omeprazole magnesium; (-)-Omeprazole magnesium
Target:  

Exosomes Proton Pump

Research Areas:  

Endocrinology Cancer

Esomeprazole magnesium ((S)-Omeprazole magnesium) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-17021B
CAS No.: 161796-84-5
Synonyms: (S)-Omeprazole potassium salt; (-)-Omeprazole potassium salt
Esomeprazole potassium salt ((S)-Omeprazole potassium salt) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K +-ATPase in gastric parietal cells. Esomeprazole potassium salt has the potential for symptomatic gastroesophageal reflux disease research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-17022
CAS No.: 217087-09-7
Synonyms: (S)-Omeprazole magnesium trihydrate; (-)-Omeprazole magnesium trihydrate
Target:  

Exosomes Proton Pump

Research Areas:  

Endocrinology Cancer

Esomeprazole magnesium trihydrate ((S)-Omeprazole magnesium trihydrate) is a potent and orally active H +, K +-ATPase inhibitor. Esomeprazole magnesium trihydrate has the potential for upper intestinal disorders and gastroesophageal reflux disease research . Esomeprazole magnesium trihydrate acts as an exosome inhibitor by blocking the exosome release via the inhibition of V-H +-ATPases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W008614
CAS No.: 131926-99-3
Synonyms: AG-1813
Research Areas:  

Metabolic Disease

Lansoprazole sulfone (AG-1813) is an orally active and selective inhibitor of H +, K +-ATPase. Lansoprazole sulfone can significantly stimulates gastric acid secretion by inhibiting H +, K +-ATPase. Lansoprazole sulfone has potential applications in duodenal ulcer, gastric ulcer, gastroesophageal reflux disease and Zolinger Ellison disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0113S
CAS No.: 922731-01-9
Synonyms: H 16868-d3
Omeprazole-d3 (H 16868-d3) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
loading...
    loading...